XyloCor Therapeutics, a clinical-stage biopharmaceutical company specializing in gene therapies for cardiovascular disease, has released positive 12-month data from the Phase 2 portion of its Phase 1/2 clinical trial (EXACT) evaluating the safety and preliminary efficacy of gene therapy candidate XC001 (encoberminogene rezmadenovec) in patients with refractory angina. The study demonstrated sustained improvements, including increased exercise duration and reduced chest pain and symptoms, adding to earlier positive findings at 3 and 6 months, highlighting XC001’s potential as a novel therapy for refractory angina.
Refractory angina poses a significant medical challenge for patients with chronic angina, experiencing symptoms despite optimal medical therapy and being ineligible for certain interventions. These patients currently lack treatment options, impacting their quality of life and leading to increased healthcare resource utilization.
XC001 is a one-time gene therapy designed to create new blood vessels in the heart, reducing ischemic burden and chest pain associated with refractory angina. The Phase 2 trial had a primary study period of six months, followed by a 12-month follow-up. At 12 months, patients showed sustained and significant increases in exercise duration, along with reduced chest pain episodes and nitroglycerin use. Cardiac imaging confirmed the therapy’s potential mechanism, indicating a sustained reduction in ischemic burden.
Thomas Povsic, M.D., Ph.D., National Principal Investigator for the study, expressed excitement about the continuous improvements seen at 12 months, signaling a promising advancement in gene therapy for cardiovascular disease. The robust mechanistic evidence supports XC001’s development and suggests potential long-term benefits with a single treatment.
Al Gianchetti, President and CEO of XyloCor, expressed confidence in transforming outcomes in cardiovascular disease based on the 12-month results, reinforcing their leading role in gene therapy for cardiovascular conditions.
Dedicated to developing best-in-class gene therapies for cardiovascular disease, XyloCor Therapeutics is also making progress with XC002, its second preclinical investigational product aimed at treating cardiac tissue damage resulting from heart attacks.
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha™ 293 cell AAV high-yield platform and the π-Omega™ plasmid high-yield platform. PackGene’s mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Related News
Skyline Therapeutics Receives FDA Orphan Drug Designation for Gene Therapy for Retinitis Pigmentosa
BOSTON & SHANGHAI, September 2, 2024 – Skyline Therapeutics, a gene therapy company focused on innovative treatments for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SKG1108....
Novavax Receives Emergency Use Authorization for Updated Covid-19 Vaccine
Novavax has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its updated Covid-19 vaccine, NVX-CoV2705, joining other vaccine manufacturers in addressing evolving virus variants. The EUA permits the use of Novavax's...
Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week
Company will present data from its successful rejuvenation of fibroblasts and keratinocytes to influential gathering of international dermatologists MOUNTAIN VIEW, Calif., Sept. 4, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and...
H5 influenza vaccines: What needs to be done to reduce the risk of a pandemic
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a robust strategy to address this and future potential...
Related Services
Plasmids GMP Services
Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE
AAV GMP Services
Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
Technology Platforms
PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE